Requires continued coverage of prescription drugs for certain medical conditions.
Impact
By requiring ongoing coverage during appeals, the bill sets a precedent that health insurers must follow regarding patients' access to necessary medications, thus reinforcing the rights of individuals with serious health needs. Insurance providers will be restricted from temporarily reducing coverage or increasing costs for patients during the appeal process, ensuring that individuals do not face delays in accessing their treatment. This change can significantly impact patient health outcomes and provide legal clarity for both patients and insurers.
Summary
Bill A2718 mandates that health insurance carriers in New Jersey continue coverage for prescription drugs prescribed to individuals with complex or chronic medical conditions or rare diseases during the appeals process for denied claims based on medical necessity. The bill defines a 'complex or chronic medical condition' as one that lacks a known cure and can significantly impair health if untreated, while a 'rare disease' is identified as affecting fewer than 200,000 individuals in the U.S. This legislation aims to protect patients who require specific medications that may be denied by health plans, especially during the appeal stages.
Contention
Key points of contention may arise regarding the extent of this coverage mandate, particularly for insurers who might feel that it imposes an unmanageable burden by limiting their discretion in evaluating claims. Concerns about potential increases in healthcare costs for all insured parties could emerge, as insurers might raise premiums to cover the expanded liability associated with continuous drug coverage during appeals. However, supporters argue that preventing gaps in necessary treatment outweighs these concerns.